[1] Henske E P, Jóźwiak S, Kingswood J C, et al. Tuberous sclerosis complex [J]. Nature Reviews Disease Primers, 2016, 2(16035.
[2] Curatolo P, Moavero R, de Vries P J. Neurological and neuropsychiatric aspects of tuberous sclerosis complex [J]. The Lancet Neurology, 2015, 14(7): 733-745.
[3] Ebrahimi-Fakhari D, Meyer S, Vogt T, et al. Dermatological manifestations of tuberous sclerosis complex (TSC) [J]. J Dtsch Dermatol Ges, 2017, 15(7): 695-700.
[4] Samuels J A. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex [J]. Clin J Am Soc Nephrol, 2017, 12(7): 1196-1202.
[5] Davis P E, Filip-Dhima R, Sideridis G, et al. Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants [J]. Pediatrics, 2017, 140(6):
[6] Taveira-DaSilva A M, Moss J. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis [J]. Clin Epidemiol, 2015, 7(249-257.
[7] Jozwiak S, Sadowski K, Borkowska J, et al. Liver Angiomyolipomas in Tuberous Sclerosis Complex-Their Incidence and Course [J]. Pediatr Neurol, 2018, 78(20-26.
[8] Osborne J P, Fryer A, Webb D. Epidemiology of tuberous sclerosis [J]. Ann N Y Acad Sci, 1991, 615(125-127.
[9] Northrup H, Krueger D A. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference [J]. Pediatr Neurol, 2013, 49(4): 243-254.
[10] Vekeman F, Magestro M, Karner P, et al. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs [J]. J Med Econ, 2015, 18(12): 1060-1070.
[11] Fryer A E, Chalmers A, Connor J M, et al. Evidence that the gene for tuberous sclerosis is on chromosome 9 [J]. Lancet, 1987, 1(8534): 659-661.
[12] Kandt R S, Haines J L, Smith M, et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease [J]. Nat Genet, 1992, 2(1): 37-41.
[13] Martin K R, Zhou W, Bowman M J, et al. The genomic landscape of tuberous sclerosis complex [J]. Nat Commun, 2017, 8(15816.
[14] O'Callaghan F J, Shiell A W, Osborne J P, et al. Prevalence of tuberous sclerosis estimated by capture-recapture analysis [J]. Lancet, 1998, 351(9114): 1490.
[15] Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis [J]. Lancet, 2008, 372(9639): 657-668.
[16] Bissler J J, Kingswood J C, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. [J]. PloS one, 2017, 12(8): e0180939.
[17] McCormack F X, Gupta N, Finlay G R, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management [J]. American journal of respiratory and critical care medicine, 2016, 194(6): 748-761.
[18] Gupta N, Vassallo R, Wikenheiser-Brokamp K A, et al. Diffuse Cystic Lung Disease. Part I [J]. Am J Respir Crit Care Med, 2015, 191(12): 1354-1366.
[19] Cudzilo C J, Szczesniak R D, Brody A S, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis [J]. Chest, 2013, 144(2): 578-585.
[20] Prizant H, Hammes S R. Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer [J]. Endocrinology, 2016, 157(9): 3374-3383.
[21] Yu J, Henske E P. mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis [J]. Lymphat Res Biol, 2010, 8(1): 43-49.
[22] Kingswood J C, d'Augeres G B, Belousova E, et al. Tuberous Sclerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients [J]. Orphanet J Rare Dis, 2017, 12(1): 2.
[23] Rabenou R A, Charles H W. Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma [J]. AJR Am J Roentgenol, 2015, 205(2): 292-301.
[24] Cai Y, Li H, Zhang Y. Assessment of Tuberous Sclerosis Complex Associated With Renal Lesions by Targeted Next-generation Sequencing in Mainland China [J]. Urology, 2017, 101(170.e171-170.e177.
[25] Amin S, Lux A, Calder N, et al. Causes of mortality in individuals with tuberous sclerosis complex [J]. Dev Med Child Neurol, 2017, 59(6): 612-617.
[26] Flum A S, Hamoui N, Said M A, et al. Update on the Diagnosis and Management of Renal Angiomyolipoma [J]. J Urol, 2016, 195(4 Pt 1): 834-846.
[27] CAI Yi, LI Han-zhong, ZHANG Yu-shi. Clinical Analysis of Selective Arterial Embolization in Treatment of Renal Angiomyolipoma 7 Patients with Tuberous Sclerosis Complex [J]. Clin Misdiagn Misther. 2016, 29(10): 19-21.
[28] FAN Hua, LI Han-zhong,JI Zhi-gang, et al. Surgical Treatment for Complex Renal Angiomyolipoma [J]. Med J Peking Union Med Coll Hosp 2018, 9(04): 346-351.
[29] Bissler J J, Kingswood J C, Radzikowska E, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial [J]. Nephrol Dial Transplant, 2016, 31(1): 111-119.
[30] Cai Y, Li H, Zhang Y. MP03-06 PRELIMINARY ANALYSIS THE EFFICACY AND SAFETY OF EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED TUBEROUS SCLEROSIS IN CHINESE PATIENTS: A SINGLE-CENTRE, SINGLE-ARM, PHASE II STUDY [J]. The Journal of Urology, 2016, 195(4, Supplement): e21.